Jazz Pharmaceuticals PLC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Jazz Pharmaceuticals filed an amendment to its 2025 Annual Report on Form 10-K to include required proxy statement information and updated certifications.
NASDAQ
Jazz Pharmaceuticals plc reports a 5% increase in total revenues for 2025, driven by strong growth in rare oncology and epilepsy products, despite declines in oxybate sales due to generic competition.
NASDAQ
Jazz Pharmaceuticals files an amendment to its 2024 Annual Report on Form 10-K to include information previously intended to be incorporated by reference from its proxy statement.
NASDAQ
Jazz Pharmaceuticals' 2024 10-K filing reveals a focus on revenue diversification, oncology and neuroscience pipeline advancement, and commitment to a high-performance culture.
NASDAQ
10-K/A: Jazz Pharmaceuticals Files Amended Annual Report: Focus on Executive Compensation and Governance
Jazz Pharmaceuticals plc has filed an amendment to its annual report, providing detailed information on executive compensation, corporate governance, and financial performance for the fiscal year ended December 31, 2023.
NASDAQ
Jazz Pharmaceuticals provides a detailed overview of its share capital structure, including authorized and issued shares, dividend policies, and repurchase options in a recent SEC filing.